{'fraction_non_alphanumeric': 0.011611030478955007, 'fraction_numerical': 0.002902757619738752, 'mean_word_length': 5.699029126213592, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Islet cell autoantigens in type 1 diabetes

would assist in determining mechanisms of disease pathogenesis. Encouraging data from trials of general immunosuppressive agents such as cyclosporin to reduce insulin requirement in diabetes [7] suggest that more specific protocols to block immune responses to primary beta cell target antigens might become safe and effective preventative therapies for disease. Procedures are therefore required to accurately identify those individuals who are at risk from disease, so that immune intervention can be administered to the appropriate individuals. In this review, recent developments in the search for relevant islet cell antigens are discussed.